Verteporfin Therapy for CNV Secondary to OHS

David A. Saperstein; Philip J. Rosenfeld; Neil M. Bressler; Robert H. Rosa; Paul Sternberg; Thomas M. Aaberg; Thomas M. Aaberg; Annemarie Weisberger

doi:10.1016/j.ophtha.2006.07.003

Verteporfin Therapy for CNV Secondary to OHS

David A. Saperstein, Philip J. Rosenfeld, Neil M. Bressler, Robert H. Rosa, Paul Sternberg, Thomas M. Aaberg, Thomas M. Aaberg, Annemarie Weisberger

Research output: Contribution to journal › Letter › peer-review

4 Scopus citations

Original language	English (US)
Pages (from-to)	2371.e1-2371.e3
Journal	Ophthalmology
Volume	113
Issue number	12
DOIs	https://doi.org/10.1016/j.ophtha.2006.07.003
State	Published - Dec 2006
Externally published	Yes

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1016/j.ophtha.2006.07.003

Cite this

@article{c8e4e0abff494e8886ded017af669c3b,

title = "Verteporfin Therapy for CNV Secondary to OHS",

author = "Saperstein, {David A.} and Rosenfeld, {Philip J.} and Bressler, {Neil M.} and Rosa, {Robert H.} and Paul Sternberg and Aaberg, {Thomas M.} and Aaberg, {Thomas M.} and Annemarie Weisberger",

note = "Funding Information: The study was supported financially by Novartis Pharma AG, Basel, Switzerland, and QLT Inc., Vancouver, Canada. The Johns Hopkins University, but not Dr Bressler, is paid for consulting services provided by Dr Bressler to Novartis Pharma. The terms of this institutional consulting arrangement are managed by the Johns Hopkins University in accordance with its conflict-of-interest policies. Drs Saperstein, Rosenfeld, and Sternberg have indicated that they are paid consultants of Novartis Pharma and/or QLT (which also may include travel expenses at meetings, participation in a speakers bureau, or honoraria). Dr Weisberger is an employee of Novartis Pharma and owns stock in Novartis Pharma. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.",

year = "2006",

month = dec,

doi = "10.1016/j.ophtha.2006.07.003",

language = "English (US)",

volume = "113",

pages = "2371.e1--2371.e3",

journal = "Ophthalmology",

issn = "0161-6420",

publisher = "Elsevier Inc.",

number = "12",

}

TY - JOUR

T1 - Verteporfin Therapy for CNV Secondary to OHS

AU - Saperstein, David A.

AU - Rosenfeld, Philip J.

AU - Bressler, Neil M.

AU - Rosa, Robert H.

AU - Sternberg, Paul

AU - Aaberg, Thomas M.

AU - Weisberger, Annemarie

N1 - Funding Information: The study was supported financially by Novartis Pharma AG, Basel, Switzerland, and QLT Inc., Vancouver, Canada. The Johns Hopkins University, but not Dr Bressler, is paid for consulting services provided by Dr Bressler to Novartis Pharma. The terms of this institutional consulting arrangement are managed by the Johns Hopkins University in accordance with its conflict-of-interest policies. Drs Saperstein, Rosenfeld, and Sternberg have indicated that they are paid consultants of Novartis Pharma and/or QLT (which also may include travel expenses at meetings, participation in a speakers bureau, or honoraria). Dr Weisberger is an employee of Novartis Pharma and owns stock in Novartis Pharma. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.

PY - 2006/12

Y1 - 2006/12

UR - http://www.scopus.com/inward/record.url?scp=33751510880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751510880&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2006.07.003

DO - 10.1016/j.ophtha.2006.07.003

M3 - Letter

C2 - 17157140

AN - SCOPUS:33751510880

SN - 0161-6420

VL - 113

SP - 2371.e1-2371.e3

JO - Ophthalmology

JF - Ophthalmology

IS - 12

ER -

Verteporfin Therapy for CNV Secondary to OHS

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this